Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.
Eye (Lond)
; 18(9): 893-9, 2004 Sep.
Article
in En
| MEDLINE
| ID: mdl-15002024
ABSTRACT
AIMS:
To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vs latanoprost in subjects with exfoliation glaucoma (XFG).METHODS:
A 3-month prospective, single-masked, active-controlled, parallel comparison performed in six centres in Greece that randomized subjects in a 1 1 ratio to either latanoprost in the evening (2000 hours) and placebo in the morning (0800 hours), or timolol twice daily (0800 and 2000 hours).RESULTS:
In all, 103 subjects completed the study. After 3 months of chronic dosing, the latanoprost group exhibited a trend to a greater diurnal IOP reduction from an untreated baseline (24.9+/-3.2-17.4+/-2.9) compared with timolol (24.7+/-2.8-18.3+/-1.9 mmHg) (P=0.07). Latanoprost showed a significantly greater IOP reduction at 0800 hours (-8.5 vs -6.0 mm Hg for timolol, P<0.0001) whereas no difference was observed between the two medications at 1000, 1400, and 2000 hours after a Bonferroni Correction. In addition, latanoprost demonstrated a narrower range of diurnal IOP (2.4) than timolol (3.2 mmHg)(P=0.0017). Safety was similar between groups, except there was more conjunctival hyperaemia with latanoprost (n=8) than timolol (n=1)(P=0.01).CONCLUSIONS:
This study suggests that latanoprost provides a statistically lower 0800-hour IOP and better range of IOP than timolol in the treatment of XFG glaucoma.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostaglandins F, Synthetic
/
Timolol
/
Glaucoma, Open-Angle
/
Exfoliation Syndrome
/
Antihypertensive Agents
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eye (Lond)
Journal subject:
OFTALMOLOGIA
Year:
2004
Document type:
Article
Affiliation country:
Grecia